Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Recruiting now · Phase 1
Conditions studied: Advanced or Metastatic Solid Tumor, Liver Failure
In brief
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Key facts
- Study ID
- NCT04617522
- Run by
- Gilead Sciences
- People needed
- 30
- Starts
- 2021-04-06
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-06-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hospital Universitario Virgen del Rocío — Seville, Spain (enrolling)
- Christiana Care Health Services — Newark, Delaware, United States (enrolling)
- University of Maryland — Baltimore, Maryland, United States (enrolling)
- Istituto Nazionale Tumori IRCCS Fondazione G. Pascale — Naples, Italy (enrolling)
- Institut Català d'Oncologia - L'Hospitalet de Llobregat — Barcelona, Spain (enrolling)
- Oncology Consultants, P.A. — Houston, Texas, United States (enrolling)
- The University of Texas M.D. Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Texas Liver Institute — San Antonio, Texas, United States (enrolling)
- NEXT Oncology — San Antonio, Texas, United States (enrolling)
- Institut Bergonie Medical Oncology — Bordeaux, France (enrolling)
- Centre Leon Berard — Lyon, France (enrolling)
- Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain — Saint-Herblain, France (enrolling)
- Instituto Europeo di Oncologia — Milan, Italy (enrolling)
- NEXT Austin — Austin, Texas, United States
- Pacific Shores Medical Group — Long Beach, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.